FDA Won't Fast-Track Astra Cancer Drug

AstraZeneca failed to win accelerated approval of a cancer drug in the U.S., dealing a blow to its new drug-development pipeline, a key plank of its defense in fighting off Pfizer's $120 billion takeover bid.



from WSJ.com: US Business http://ift.tt/1o5VawS

via IFTTT